Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Credit Woes Hitting Even Pharma

Executive Summary

The pharmaceutical industry may take risks with R&D, but its disciplined approach to the balance sheet has helped insulate it from the rapidly spreading global credit mess. But even pharma will not be completely shielded

You may also be interested in...

New Funding Source For Cash-Strapped BioPharma

New ‘growth equity’ focus at Novo A/S to fund late-stage and commercially focused life sciences companies

King’s Dogged Pursuit of Alpharma Comes Up Aces

The combined specialty pharma company to be a leader in abuse-resistant pain meds.

BIO Says Tax Revisions Would Relax Tight Money For Biotechs

Tax measures that provide cash and encourage investment in the biotech sector should be part of economic stimulus package, group says.

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts